Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

The acquisition was announced on Monday with James Walker, CEO of Agostini’s Pharmaceutical Group, presents at MDJL’s Carifta ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs. Lilly said ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Contracts on the S&P 500 ( ES=F) and the tech-heavy Nasdaq 100 ( NQ=F) were down 0.2%. Dow Jones Industrial Average futures ( ...

The S&P 500 ( ^GSPC) and the tech-heavy Nasdaq Composite ( ^IXIC) hovered just above the flatline. The Dow Jones Industrial ...

Japan's SoftBank is reportedly close to becoming the biggest investor in generative artificial intelligence leader OpenAI, ...

What are the Magnificent Seven stocks? How much market cap weighting do AAPL, MSFT, GOOGL, AMZN, META, TSLA and NVDA have on ...